Overview

Performance of the Travoprost Intraocular Implant

Status:
COMPLETED
Trial end date:
2023-11-02
Target enrollment:
Participant gender:
Summary
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months
Phase:
PHASE2
Details
Lead Sponsor:
Glaukos Corporation